key: cord-0960020-i6oy9wnq authors: Caronna, Edoardo; Alpuente, Alicia; Torres‐Ferrus, Marta; Pozo‐Rosich, Patricia title: Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios date: 2021-08-07 journal: Headache DOI: 10.1111/head.14197 sha: 66fa68486f801819ad9b343469045cb819f89784 doc_id: 960020 cord_uid: i6oy9wnq One year after the outbreak of coronavirus disease 2019 (COVID‐19), referrals for persistent headache, often defined as “post‐COVID headache,” have become increasingly common in outpatient headache clinics. However, it is important to take into consideration that this term may include a spectrum of clinically different headache types. We describe three cases of migraine‐like headaches in individuals with a history of mild COVID‐19 infection to demonstrate some of the different phenotypes of persistent headaches seen. These cases highlight the importance of a careful evaluation when assessing the complexities of “post‐COVID headache” as well as the need to further investigate the different, underlying, pathophysiological mechanisms. frontally located, throbbing in quality, with a moderate-severe pain intensity, and associated with nausea, photophobia, and phonophobia. She reported that it differed from her usual migraine in that the pain since onset was constant. This constant pain was most likely the reason why the patient started overusing acute medication (paracetamol and nonsteroidal anti-inflammatory drugs) during the first 2 months, although later the lack of pain relief made her reduce her analgesic intake. The patient also started noticing allodynia while combing her hair. The patient first visited our headache clinic at the end of October 2020 to discuss persistent headache. She also reported fatigue and insomnia. Results from a CT scan with contrast, lab work, and a neurological examination were within the norm and did not suggest the presence of secondary causes. The patient did not have hypertension or any new onset comorbidity. The patient was instructed on lifestyle changes and, given the disabling nature of her headaches and other symptomology, was offered combined preventive treatment with amitriptyline 25 mg QD, also beneficial in treating her insomnia, and onabotulinumtoxinA (BTX) 195U based on her chronic migrainelike phenotype. Because of the patient's initial reluctance toward BTX, we began with amitriptyline only. After 4 weeks, the patient's sleep quality had improved; however, she continued to experience headache almost daily, although with a reduction in intensity. We then added BTX to her treatment and after 3 months, the patient experienced a reduction in headache frequency to around 8-10 days/ month and a return in character to her usual migraine. The patient's allodynia also disappeared. Her symptoms remained stable throughout the second cycle of BTX. A 55-year-old woman, with no personal or family history of a primary headache disorder and no other comorbidities, who underwent menopause at age 51, had a mild COVID-19 infection. She exhibited symptoms of headache, anosmia/ageusia, cough, shortness of breath, malaise, and diarrhea at the end of March 2020. The presence of COVID-19 was confirmed by a positive RT-PCR. Pneumonia was ruled out with a chest X-ray. The patient's headache started a few days after the appearance of her other symptoms. Headache characteristics included holocranial location, moderate severity, and tightness/pressure in terms of type of pain although the patient also reported moments of more severe, throbbing pain. Headache was accompanied by photophobia, phonophobia, and nausea. The patient was unable to engage in her usual physical exercise due to worsening of pain with movement. She had constant pain following headache onset and was taking paracetamol daily. The patient first visited our headache clinic at the beginning of July 2020 because of the presence of persistent headache. Furthermore, she was still experiencing hyposmia, fatigue, and insomnia. An MRI of the brain with MR angiography, blood tests, as well as a neurological examination were performed but did not yield any secondary causes. We discussed lifestyle changes with the TA B L E 1 Main features of the three patients presented patient and, based on the same rationale as in Patient 1, a combined preventive treatment plan of amitriptyline 25 mg QD coupled with BTX 195U were initiated immediately. Three months later, the patient's sleep quality had improved alongside an important reduction in both headache frequency (1-2 headache days/week) and severity (50%-75% reduction). On headache days with migraine features, the patient displayed a good response to almotriptan 12.5 mg. The patient remained clinically stable with two subsequent BTX administrations, although she did report the effects of the treatment "wearing off" prior to each injection. was controlled, sleep quality had partially improved, but the patient did not report any significant clinical changes in his persistent headaches. BTX 195U was added to the patient's treatment plan but was discontinued after two cycles due to a lack of improvement. Rizatriptan 10 mg was ineffective in treating migraine-like days. During the follow-up, the patient started reporting other symptoms such as cognitive impairment, memory loss, heart palpitations, and dizziness, for which he had scheduled a visit at a memory unit and a cardiology clinic, respectively. On the patient's last visit in April 2021, escitalopram 10 mg QD was started due to changes in mood. He was still experiencing disabling, daily, and constant headache and had not returned to work or his usual activities. Although we are aware of a potentially wide spectrum of persistent post-COVID headaches, we report these three cases as they (1) demonstrate the existence of phenotypically similar (i.e., all of these cases had migraine-like features and were found in patients having undergone a mild COVID-19 infection) but considerably different headache subtypes and (2) represent some of the patients we have observed in clinical practice (Table 1) to headache and (2) directly affect headache prognosis. 14, 15 Thus, future research studies should focus on studying how these aspects (i.e., migraine history, migraine-like features, headache in the acute phase, headache onset post-COVID, presence of associated symptoms) interact in determining specific clinical phenotypes, to better understand their mechanisms and define the best therapeutic strategies. We acknowledge the collaboration of Angela Marti-Marca. Characteristics of SARS-CoV-2 and COVID-19 World Health Organization Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution Phenotypic characterization of acute headache attributed to SARS-CoV-2: an ICHD-3 validation study on 106 hospitalized patients Lifting the mask on neurological manifestations of COVID-19 Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms Post-acute COVID-19 syndrome 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Persistent headache and persistent anosmia associated with COVID-19 Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 How COVID-19 affects the brain Sleep disorders and migraine: review of literature and potential pathophysiology mechanisms Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization Migraine and its psychiatric comorbidities Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios